1. A method for identifying a user equipment (UE) in a system architecture evolved (SAE) network, comprising:
receiving, by the UE, a system architecture evolved (SAE)-temporary mobile subscriber identity (SAE-TMSI) from a mobility management entity (MME) of the SAE network, wherein the SAE-TMSI comprises: a resource pool identifier (pool-ID), a mobility management entity identifier (MME-ID); and a UE temporary identifier;
sending, by the UE, the SAE-TMSI to the MME or a new MME when the UE accesses the SAE network next time, wherein the SAE-TMSI is used for the MME or the new MME to identify the UE; and
wherein the pool-ID is unique in public land mobile network (PLMN), the MME-ID is unique in a resource pool, and the UE temporary identifier is unique in an MME.
2. The method according to claim 1, wherein the SAE-TMSI further comprises a public land mobile network identifier (PLMN-ID).
3. The method according to claim 1, wherein the SAE-TMSI is used for the MME of the SAE network or the new MME to identify the UE comprises:
the UE temporary identifier of the SAE-TMSI is used for the MME of the SAE network or the new MME to identify the UE.
4. A system for identifying a user equipment (UE), comprising:
an evolved Radio Access Network (RAN) entity, configured to receive a system architecture evolved (SAE)-Temporary Mobile Subscriber Identity (SAE-TMSI) allocated to the UE when the UE accesses the SAE network, wherein the SAE-TMSI at least comprises:
an identifier for a resource pool (pool-ID), an identifier for a mobility management entity (MME-ID) and a UE temporary identifier;
the MME, configured to identify the UE according to the SAE-TMSI, wherein the pool-ID is unique in public land mobile network (PLMN), the MME-ID is unique in the resource pool, and the UE temporary identifier is unique in the MME.
5. The system according to claim 4, wherein the evolved RAN entity is further configured to select the MME according to the pool-ID and the MME-ID.
6. The system according to claim 4, wherein the evolved RAN entity is further configured to select the MME according to a principle, if no MME in the resource pool corresponding to the evolved RAN entity is relevant to the pool-ID and the MME-ID in the SAE-TMSI.
7. The system according to claims 4, wherein the SAE-TMSI further comprises a public land mobile network identifier (PLMN-ID).
8. The system according to claims 4, wherein the MME is further configured to obtain address information of an old MME of the UE and obtain context or identifier information of the UE from the old MME according to the address information.
9. The system according to claim 4, wherein the evolved RAN entity is further configured to select the MME according to a principle, if the evolved RAN entity determines that an old Track Area Identifier (TAI) of the UE does not belong to the resource pool.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method for enhancing autophagy in cells comprising providing a mono-carbonyl analog of curcumin having a formula of
wherein R is independently selected from the group consisting of CF3, OH and OCH3.
2. The method of claim 1, wherein said R is CF3 and the mono-carbonyl analog of curcumin having a formula of A2:
3. The method of claim 1, wherein said R is OH and the mono-carbonyl analog of curcumin having a formula of B3:
4. The method of claim 1, wherein said R is OCH3 and the mono-carbonyl analog of curcumin having a formula of C1:
5. A method of treating neurodegenerative diseases comprising administering a composition comprising a mono-carbonyl analog of curcumin having a formula of
wherein R is selected from the group consisting of CF3, OH and OCH3 to a subject in need thereof.
6. The method according to claim 5, wherein the neurodegenerative diseases comprising Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and Creutzfeldt-Jakob disease.
7. The method according to claim 5, wherein the mono-carbonyl analog is
the mono-carbonyl analogs is administered at 1.62 mgkg to 28.38 mgkg body weight of the subject in need thereof.
8. The method according to claim 5, wherein the composition is administered to the subject in need thereof via oral administration, intravenous injection or both.
9. The method according to claim 5, wherein said R is CF3 and the mono-carbonyl analog of curcumin comprises a formula of A2:
10. The method according to claim 5, wherein said R is OH and the mono-carbonyl analog of curcumin comprises a formula of B3:
11. The method according to claim 5, wherein said R is OCH3 and the mono-carbonyl analog of curcumin comprises a formula of C1:
12. A method of enhancing lysosome biogenesis in cells comprising providing a mono-carbonyl analog of curcumin having a formula of
wherein R is OCH3.
13. The method of claim 12, wherein the mono-carbonyl analog of curcumin comprises a formula of C1:
14. The method of claim 12, wherein the cells are neuronal cells.
15. The method of claim 12, wherein the cells are non-neuronal cells.